{
  "patientId": "67890",
  "demographics": {
    "name": "John Smith",
    "dob": "1978-06-15",
    "gender": "Male",
    "address": "123 Oak Ave, Metroville, USA",
    "phone": "555-6789",
    "insurance": "Aetna PPO - Policy #AET-JS-197867",
    "referringPhysician": "Dr. Sarah Collins (Hematology/Oncology)",
    "emergencyContact": "Mary Smith (Wife) - 555-6780",
    "advanceDirectives": "Full Code (On File, verified 04/08/2025)",
    "supportServices": "Bone Marrow Transplant (BMT) Coordinator assigned. Social Work, Psychology, and Nutrition consults completed as part of pre-transplant workup.",
    "mobility": "Ambulatory without assistance. ECOG Performance Status 0."
  },
  "diagnosis": {
    "primary": "Acute Myeloid Leukemia (AML), Not Otherwise Specified (NOS)",
    "datePathologicDiagnosis": "01/10/2025 (Initial Bone Marrow Biopsy)",
    "pathologicStage": "N/A (Staging for AML is based on risk stratification, not solid tumor staging). ELN 2017 Risk: Intermediate.",
    "symptomsAtPresentation": "One-week history of progressive fatigue, easy bruising on extremities, and low-grade fevers.",
    "pathologyFindings": [
      "Initial Bone Marrow Biopsy (01/10/2025): Hypercellular marrow (90%) with 65% myeloblasts. Auer rods identified. Flow cytometry confirmed myeloid lineage (CD13+, CD33+, CD117+, MPO+).",
      "Cytogenetics: Normal Karyotype (46,XY).",
      "Molecular Panel: NPM1 wild-type, FLT3-ITD negative, CEBPA wild-type.",
      "Post-Consolidation Bone Marrow Biopsy (04/05/2025): Morphologic and MRD-negative Complete Remission (CR). Normocellular marrow with <5% blasts and evidence of trilineage hematopoiesis."
    ],
    "priorTreatmentSummary": "Patient achieved a complete remission after one cycle of standard '7+3' induction chemotherapy (Daunorubicin/Cytarabine) and completed one cycle of consolidation with High-Dose Cytarabine (HiDAC). He is now proceeding to allogeneic transplant as definitive consolidation.",
    "relevantHistory": "No significant past medical history. Works as a software engineer. Married with two children.",
    "baselineStatus": "ECOG 0. In complete remission from AML. Admitted to the BMT unit for conditioning therapy."
  },
  "treatmentPlan": {
    "radOnc": "Dr. David Lee",
    "transplantPhysician": "Dr. Robert Evans (BMT Service)",
    "hemeOnc": "Dr. Sarah Collins",
    "treatmentSite": "Total Body",
    "intent": "Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant (HCT)",
    "modality": "Total Body Irradiation (TBI) followed by high-dose Cyclophosphamide",
    "totalDose": "12 Gy",
    "fractionation": "6 fx",
    "rtRxDetails": "12 Gy in 6 fractions, delivered twice-daily (BID) over 3 consecutive days (2 Gy/fx).",
    "targetVolumeSummary": "The target is the entire body, from the vertex of the skull to the soles of the feet. Custom lead blocks will be used to shield the lungs to reduce the total dose and limit the risk of pneumonitis.",
    "techniqueSummary": "Opposed lateral fields delivered at an extended source-to-surface distance (SSD) to encompass the entire body. Patient is treated lying on their side (lateral decubitus) on a specialized cart, treating one side then flipping to treat the other. Dose rate is reduced to improve tolerance.",
    "concurrentChemo": "High-dose Cyclophosphamide (post-TBI)",
    "detailedConcurrentChemo": "Patient will receive Cyclophosphamide (60 mg/kg/day IV) for 2 days following completion of TBI, as part of the conditioning regimen.",
    "medications": [
      "Levofloxacin, Fluconazole, Acyclovir for infection prophylaxis.",
      "Ondansetron + Olanzapine for high-dose antiemetic prophylaxis.",
      "IV fluids for hydration.",
      "Tacrolimus/Methotrexate for Graft-vs-Host Disease (GVHD) prophylaxis, to start post-transplant.",
      "Leucovorin rinse for mucositis prevention."
    ],
    "therapistAlerts": [
      "This is a TBI procedure. Double-check all calculations, patient positioning, and shielding with physics before every fraction.",
      "Patient is at very high risk for nausea/vomiting. Ensure antiemetics have been administered pre-treatment as prescribed.",
      "In-vivo dosimeters (diodes) must be placed at specified points on the patient's skin for every fraction to verify dose delivery. Record all diode readings.",
      "Ensure custom lung blocks are correctly placed and secured for each treatment.",
      "Communicate clearly with the patient throughout the long setup and treatment process. Patient may feel anxious and unwell."
    ]
  },
  "radiationOncologyData": {
    "ctSimulation": {
      "simulationDate": "04/10/2025",
      "setupInstructions": "Two setups simulated: Patient lying on right side (Left Lateral) and left side (Right Lateral) on a low gurney. A custom Vac-Lok bag is used for immobilization. Knees bent, arms holding a support bar for comfort and stability.",
      "immobilization": "Vac-Lok bag, patient positioning sponges.",
      "referenceMarks": "Marks placed on the patient for alignment to room lasers at the level of the umbilicus.",
      "scanner": "CT scanner with large bore and extended field-of-view capability.",
      "ctNotes": "Non-contrast CT scan acquired for dose calculation and localization of lungs for shielding block design. Patient tolerated simulation well. Diode placement locations (head, neck, chest, abdomen, pelvis, knee, ankle) were tattooed."
    },
    "dosimetry": {
      "planId": "JS67890_TBI",
      "planStatus": "Final - Approved by Dr. David Lee (04/12/2025)",
      "rx": "12 Gy / 6 fx (BID over 3 days)",
      "technique": "TBI - Opposed Lateral Fields",
      "energy": "6MV",
      "tps": "Manual Calculation & In-Vivo Dosimetry Verification",
      "constraints": "Total Lung Dose < 8 Gy (achieved with custom lead blocks).",
      "planNotes": "Myeloablative TBI conditioning. In-vivo dosimetry with diodes is mandatory for all fractions to verify dose delivery to midplane abdomen (prescription point) and tolerance points (head, feet). Dose rate is reduced to 10 cGy/min.",
      "igrtProtocol": {
        "frequency": "N/A",
        "type": "Clinical Setup Verification",
        "alignment": "Alignment to room lasers at tattooed reference marks. Light field used to confirm body coverage and position of lung blocks.",
        "tolerances": "N/A"
      },
      "qaChecks": [
        { "date": "2025-04-12", "type": "TBI Beam Calibration (Extended SSD)", "by": "Medical Physicist (SD)", "result": "Pass. Output at extended distance verified." }
      ],
      "fieldDetails": [
        { "fieldName": "Right Lateral", "fieldSize": "40.0 x 40.0 cm (Open)", "gantryAngle": "90", "energy": "6MV", "ssd": "Extended SSD (~400 cm)" },
        { "fieldName": "Left Lateral", "fieldSize": "40.0 x 40.0 cm (Open)", "gantryAngle": "270", "energy": "6MV", "ssd": "Extended SSD (~400 cm)" }
      ]
    },
    "treatmentDelivery": {
      "fractions": [
        {
          "fractionNumber": "1 & 2", "totalFractions": 6, "date": "2025-04-15", "machine": "LINAC 2 (TBI Setup)", "therapistInitials": "AM, LW",
          "recordedFields": [{ "fieldName": "R/L Laterals", "notes": "BID treatment delivered." }],
          "energiesUsed": "6MV", "setupVerification": "Tolerances Met", "immobilizationDevicesChecked": "TBI cart, Vac-Lok", "setupAdjustments": "None", "organTargetChecks": "Lung blocks confirmed in place. Diode placement verified.", "imagingType": "None (Clinical Setup)", "igrtMatchQuality": "N/A", "igrtApprovedBy": "DL (Physician)",
          "patientTolerance": "Fair", "generalSideEffects": "Moderate nausea after second fraction, managed with IV antiemetics. Fatigue.", "siteSpecificSideEffects": "None", "painAssessment": "0/10", "patientConcerns": "Concerned about nausea.", "instructionsGiven": "Reassured patient that antiemetics will be adjusted as needed.", "billingCodes": "77499, 77336", "dailyNotes": "Completed first day of BID TBI. Patient tolerated the long setup. Diode readings recorded and within tolerance."
        },
        {
          "fractionNumber": "3 & 4", "totalFractions": 6, "date": "2025-04-16", "machine": "LINAC 2 (TBI Setup)", "therapistInitials": "AM, LW",
          "recordedFields": [{ "fieldName": "R/L Laterals", "notes": "BID treatment delivered." }],
          "energiesUsed": "6MV", "setupVerification": "Tolerances Met", "immobilizationDevicesChecked": "TBI cart, Vac-Lok", "setupAdjustments": "None", "organTargetChecks": "Lung blocks confirmed in place. Diode placement verified.", "imagingType": "None (Clinical Setup)", "igrtMatchQuality": "N/A", "igrtApprovedBy": "Therapist",
          "patientTolerance": "Fair", "generalSideEffects": "Nausea better controlled with adjusted pre-meds. Significant fatigue.", "siteSpecificSideEffects": "Early signs of parotitis (mild jaw tenderness).", "painAssessment": "1/10 (jaw)", "patientConcerns": "Feeling very tired.", "instructionsGiven": "Encouraged rest between fractions. Sips of water and hard candy for parotitis.", "billingCodes": "77499", "dailyNotes": "Completed second day of TBI. Diode readings consistent. Patient is fatigued but cooperative."
        },
        {
          "fractionNumber": "5 & 6", "totalFractions": 6, "date": "2025-04-17", "machine": "LINAC 2 (TBI Setup)", "therapistInitials": "AM, LW",
          "recordedFields": [{ "fieldName": "R/L Laterals", "notes": "BID treatment delivered." }],
          "energiesUsed": "6MV", "setupVerification": "Tolerances Met", "immobilizationDevicesChecked": "TBI cart, Vac-Lok", "setupAdjustments": "None", "organTargetChecks": "Lung blocks confirmed in place. Diode placement verified.", "imagingType": "None (Clinical Setup)", "igrtMatchQuality": "N/A", "igrtApprovedBy": "DL (Physician)",
          "patientTolerance": "Poor", "generalSideEffects": "Severe fatigue, nausea, diarrhea beginning.", "siteSpecificSideEffects": "Mild mucositis, parotitis persists.", "painAssessment": "2/10 (mouth/jaw)", "patientConcerns": "Anxious to be done.", "instructionsGiven": "End of TBI instructions provided to patient and inpatient team. Focus on hydration and supportive care.", "billingCodes": "77499, 77427", "dailyNotes": "Final day of TBI completed. Patient very fatigued. Diode readings for entire course reviewed by physics and approved. Patient now ready for Cyclophosphamide portion of conditioning."
        }
      ]
    }
  },
  "progressNotes": [
    { "date": "03/25/2025", "author": "Dr. Robert Evans (BMT)", "type": "BMT Consult Note", "summary": "Patient seen for allo-HCT consult. He has intermediate-risk AML and is in a durable CR1 post-consolidation. He has a good performance status. Recommends proceeding with a Matched Unrelated Donor (MUD) allo-HCT for the best chance of long-term cure. Standard myeloablative conditioning with Cyclophosphamide/TBI is planned. Discussed risks, benefits, and alternatives at length with patient and wife. They wish to proceed. MUD search has identified a suitable 10/10 donor." },
    { "date": "04/08/2025", "author": "Dr. David Lee (Rad Onc)", "type": "TBI Consult Note", "summary": "Patient referred by BMT for TBI planning as part of conditioning for MUD allo-HCT. We have discussed the TBI procedure, schedule (12 Gy in 6 fractions BID), and the extensive potential for acute (nausea, fatigue, mucositis, parotitis, diarrhea) and late (cataracts, secondary malignancy, infertility, endocrine dysfunction, pneumonitis) side effects. Patient and wife verbalize understanding and consent to proceed with TBI. CT Simulation scheduled." }
  ]
}
